Caffeine vs other methylxanthines
Moderate‐severe neurodevelopmental impairment at 18 to 26 months ‐ not measured · preterm infants
The review found no eligible studies for this question.
1 finding from 1 review
- Caffeine versus other methylxanthines for the prevention and treatment of apnea in preterm infants 2023 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedNo studies found